Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024
Perspective Therapeutics, Inc. (CATX)
Company Research
Source: GlobeNewswire
SEATTLE, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ?Perspective Therapeutics, Inc.?(“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced updates featuring the Company’s alpha-particle radiopharmaceuticals at the World Molecular Imaging Congress (WMIC) 2024, held on September 9-13, 2024, in Québec, Canada. “We are pleased with the additional data that support the continued development of our alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO. “The data demonstrate the need for customized chelators to maximize stability and targeted delivery of potent alpha-particles. Additionally, our novel FAP-targeting candidate, PSV-359, continues to show favorable safety and strong efficacy profiles in preclinical studies.” Presentation One: Preclinical evaluation of [203/212Pb]Pb-PSV-359 for imaging and alpha-particle therapy of cancers expres
Show less
Read more
Impact Snapshot
Event Time:
CATX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CATX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CATX alerts
High impacting Perspective Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CATX
News
- Perspective Therapeutics, Inc. (NYSE: CATX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock, down previously from $20.00.MarketBeat
- Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical SymposiumGlobeNewswire
- Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024GlobeNewswire
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 ResultsGlobeNewswire
- Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial ResultsGlobeNewswire
CATX
Earnings
- 11/12/24 - In-Line
CATX
Sec Filings
- 11/21/24 - Form 8-K
- 11/15/24 - Form 8-K
- 11/14/24 - Form SC
- CATX's page on the SEC website